We understand how anxious and excited you are to learn more about the results of this trial. We are too! Please bear with us as we continue to process the data. We expect to have it available towards the end of October.

Prior to the passing of this Act, there were few, if any, companies developing treatments for rare diseases. Because of such low prevalence rates, companies considered these drugs too costly to produce.

In order to provide the necessary ongoing support to private industry for researching and producing orphan drugs, the FDA, through the Orphan Drug Act, offers:

• A tax credit of 50% off the cost of conducting human trials for orphan drugs
• Research grants for clinical trials of new therapies to treat orphan diseases
• An exclusive marketing monopoly to the sponsoring company for 7 years post-approval
• Waiver of Prescription Drug User Fee Act (PDUFA) filing fees, which are currently about $1,000,000 per application

Since passing the Orphan Drug Act in 1983, the FDA has provided more than 1,000 designations and has approved over 300 new products. It’s important to note that from 1973 to 1983 (before the Orphan Drug Act legislation) only 10 treatments for rare diseases were developed.

So how does the Orphan Drug Act apply to Nutra Pharma? Quite simply, we believe that one of our leading drug candidates, RPI-78M, may be eligible for Orphan Drug Status as a therapy for treating Adrenomyeloneuropathy (AMN). With an estimated 30,000 patients affected by AMN globally, having Orphan Drug Status would provide us with additional financial support during the development stage and then after we gain drug approval.

Additional Resources

• Orphan Drug Act
• Celebrating the Successes of the Orphan Drug Act (Article on FDA.gov)
• List of US Orphan Designations and Approvals
• List of European Orphan Drugs

For the past several weeks, we’ve been updating our 2008 Corporate Presentation. It’s finally complete and we’re excited to share it with you. Feel free to download a copy of the Presentation by clicking on the image above or by clicking here.

(Adobe Acrobat Reader is required to view this document. If you do not have Adobe Acrobat Reader, click here to download it.)

As the Chairman, Chief Executive Officer, and fellow investor in the Company, I am excited and pleased to share with you the recent progress we have made in our drug research.

Last week marked one of the most exciting accomplishments for our company. As many of you read in our press release; on Tuesday, our wholly-owned drug discovery subsidiary, ReceptoPharm, successfully completed its 15-month Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy (AMN).

As our first Phase II trial to be completed, this not only adds tremendous credibility to our research, but it also provides additional evidence supporting the safety and efficacy of our leading drug candidate for neurological and autoimmune disorders, RPI-78M.

Although data from the Trial is still being collected and analyzed, initial feedback from physicians involved in the trial was positive. We look forward to presenting our data by the end of September.

As part of our ongoing commitment to maintain a high level of transparency and communication with our shareholders and those interested in our company, we continue to post articles to the NPC Blog. We invite you to read our recent entries, which include in-depth commentaries about our work with Adrenomyeloneuropathy and Nontuberculous Mycobacteria. You can also opt-in to receive these posts through your email by filling out and submitting the “Blog Updates” form when you visit the blog at the above address.

In addition to the NPC Blog, we post our recent press announcements online. If you would like to receive the latest news from the Company, I invite you to subscribe to our “E-Alerts”. Just visit http://www.NutraPharma.com, fill out the “E-Alerts” form on the lower left column of the homepage and click “subscribe”. “E-Alerts” are separate from “Blog Updates”, so you will need to sign up for each individually if you would like to receive both company news and blog posts by email.

As always, if you have any additional questions or would like more information, please contact the Investor Relations Hotline at (877) 895-5647.

Sincerely yours,
Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation